|
05/01/2023
|
Summary ToggleEledon Pharmaceuticals Announces up to $185 Million Financing to Advance Tegoprubart Kidney Transplantation Clinical Trials
|
|
03/31/2023
|
Summary ToggleEledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology
|
|
03/30/2023
|
Summary ToggleEledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results
|
|
03/23/2023
|
Summary ToggleEledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023
|
|
03/23/2023
|
Summary ToggleEledon to Present Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Kidney Transplantation at the World Congress of Nephrology 2023
|
|
02/08/2023
|
Summary ToggleEledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
|
|
01/09/2023
|
Summary ToggleeGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
|
|
01/09/2023
|
Summary ToggleEledon Pharmaceuticals Provides Business and Pipeline Updates
|
|
12/21/2022
|
Summary ToggleC-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System
|
|
11/14/2022
|
Summary ToggleEledon Pharmaceuticals Reports Third Quarter 2022 Operating and Financial Results
|
